Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to DSCO
- Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
- Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA
- Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to Earnings
- Auriga Reiterates a 'Buy' on McDermott International (MDR); Upstream/Government Story Trumps Quarterly Noise
- Citi Upgrades Chile Stocks to Overweight, Downgrades Colombia Stocks to Neutral
- Baird Maintains a 'Neutral' Rating on Cephalon (CEPH), Reslizumab Mixed Results in EE Sets Back Potential for Upside
- Wedbush Removes McDonald's (MCD) from 'Best Ideas' List; Reiterates Outperform
- Piper Jaffray Maintains an 'Overweight' on Cephalon (CEPH); Buy on Weakness
Discovery Laboratories (NASDAQ: DSCO) reports Q3 loss of $0.06, even with the analyst estimate of ($0.06).
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
